Logo image of NRXP

NRX PHARMACEUTICALS INC (NRXP) Stock Fundamental Analysis

NASDAQ:NRXP - Nasdaq - US6294442099 - Common Stock - Currency: USD

2.84  +0.15 (+5.58%)

After market: 2.76 -0.08 (-2.82%)

Fundamental Rating

0

Overall NRXP gets a fundamental rating of 0 out of 10. We evaluated NRXP against 195 industry peers in the Pharmaceuticals industry. NRXP may be in some trouble as it scores bad on both profitability and health. NRXP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NRXP has reported negative net income.
In the past year NRXP has reported a negative cash flow from operations.
In the past 5 years NRXP reported 4 times negative net income.
NRXP had a negative operating cash flow in each of the past 5 years.
NRXP Yearly Net Income VS EBIT VS OCF VS FCFNRXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -456.95%, NRXP is doing worse than 95.70% of the companies in the same industry.
Industry RankSector Rank
ROA -456.95%
ROE N/A
ROIC N/A
ROA(3y)-544.09%
ROA(5y)-329.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRXP Yearly ROA, ROE, ROICNRXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

NRXP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRXP Yearly Profit, Operating, Gross MarginsNRXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for NRXP has been increased compared to 1 year ago.
NRXP has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NRXP has a worse debt to assets ratio.
NRXP Yearly Shares OutstandingNRXP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
NRXP Yearly Total Debt VS Total AssetsNRXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

NRXP has an Altman-Z score of -103.08. This is a bad value and indicates that NRXP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NRXP (-103.08) is worse than 94.09% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -103.08
ROIC/WACCN/A
WACCN/A
NRXP Yearly LT Debt VS Equity VS FCFNRXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.20 indicates that NRXP may have some problems paying its short term obligations.
NRXP has a Current ratio of 0.20. This is amonst the worse of the industry: NRXP underperforms 97.31% of its industry peers.
A Quick Ratio of 0.20 indicates that NRXP may have some problems paying its short term obligations.
NRXP has a Quick ratio of 0.20. This is amonst the worse of the industry: NRXP underperforms 96.77% of its industry peers.
Industry RankSector Rank
Current Ratio 0.2
Quick Ratio 0.2
NRXP Yearly Current Assets VS Current LiabilitesNRXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.00% over the past year.
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NRXP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.72% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.55%
EPS Next 2Y39.94%
EPS Next 3Y31.72%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRXP Yearly Revenue VS EstimatesNRXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
NRXP Yearly EPS VS EstimatesNRXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRXP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRXP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRXP Price Earnings VS Forward Price EarningsNRXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRXP Per share dataNRXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2

4.3 Compensation for Growth

NRXP's earnings are expected to grow with 31.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.94%
EPS Next 3Y31.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NRXP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NRX PHARMACEUTICALS INC

NASDAQ:NRXP (2/5/2025, 8:17:29 PM)

After market: 2.76 -0.08 (-2.82%)

2.84

+0.15 (+5.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners4.75%
Inst Owner Change0%
Ins Owners26.51%
Ins Owner Change4.6%
Market Cap34.34M
Analysts82.22
Price Target32.3 (1037.32%)
Short Float %13.12%
Short Ratio0.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)42.79%
Min EPS beat(2)5.49%
Max EPS beat(2)80.09%
EPS beat(4)3
Avg EPS beat(4)20.91%
Min EPS beat(4)-31.91%
Max EPS beat(4)80.09%
EPS beat(8)5
Avg EPS beat(8)14.6%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.06%
EPS NQ rev (1m)50.26%
EPS NQ rev (3m)29.63%
EPS NY rev (1m)0%
EPS NY rev (3m)31.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0
BVpS-1.56
TBVpS-1.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -456.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-544.09%
ROA(5y)-329.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.2
Quick Ratio 0.2
Altman-Z -103.08
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)220%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.43%
EPS Next Y51.55%
EPS Next 2Y39.94%
EPS Next 3Y31.72%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.54%
OCF growth 3YN/A
OCF growth 5YN/A